Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
BSTC's Cash to Debt is ranked higher than
85% of the 1493 Companies
in the Global Biotechnology industry.

( Industry Median: 48.04 vs. BSTC: No Debt )
BSTC' s 10-Year Cash to Debt Range
Min: 0.06   Max: No Debt
Current: No Debt

Equity to Asset 0.97
BSTC's Equity to Asset is ranked higher than
99% of the 1113 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. BSTC: 0.97 )
BSTC' s 10-Year Equity to Asset Range
Min: -5.34   Max: 0.98
Current: 0.97

-5.34
0.98
Interest Coverage No Debt
BSTC's Interest Coverage is ranked higher than
87% of the 680 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. BSTC: No Debt )
BSTC' s 10-Year Interest Coverage Range
Min: 80.45   Max: 9999.99
Current: No Debt

80.45
9999.99
F-Score: 6
Z-Score: 160.60
M-Score: -1.48
WACC vs ROIC
3.32%
73.26%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 55.73
BSTC's Operating margin (%) is ranked higher than
98% of the 1195 Companies
in the Global Biotechnology industry.

( Industry Median: -79.37 vs. BSTC: 55.73 )
BSTC' s 10-Year Operating margin (%) Range
Min: -296.7   Max: 54.91
Current: 55.73

-296.7
54.91
Net-margin (%) 36.77
BSTC's Net-margin (%) is ranked higher than
96% of the 1195 Companies
in the Global Biotechnology industry.

( Industry Median: -72.15 vs. BSTC: 36.77 )
BSTC' s 10-Year Net-margin (%) Range
Min: -300.13   Max: 63.95
Current: 36.77

-300.13
63.95
ROE (%) 22.58
BSTC's ROE (%) is ranked higher than
96% of the 1371 Companies
in the Global Biotechnology industry.

( Industry Median: -28.22 vs. BSTC: 22.58 )
BSTC' s 10-Year ROE (%) Range
Min: -343.89   Max: 61.21
Current: 22.58

-343.89
61.21
ROA (%) 21.85
BSTC's ROA (%) is ranked higher than
98% of the 1497 Companies
in the Global Biotechnology industry.

( Industry Median: -22.65 vs. BSTC: 21.85 )
BSTC' s 10-Year ROA (%) Range
Min: -156.91   Max: 53.14
Current: 21.85

-156.91
53.14
ROC (Joel Greenblatt) (%) 290.52
BSTC's ROC (Joel Greenblatt) (%) is ranked higher than
99% of the 1457 Companies
in the Global Biotechnology industry.

( Industry Median: -358.68 vs. BSTC: 290.52 )
BSTC' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -406600   Max: 275.15
Current: 290.52

-406600
275.15
Revenue Growth (3Y)(%) 6.70
BSTC's Revenue Growth (3Y)(%) is ranked higher than
79% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. BSTC: 6.70 )
BSTC' s 10-Year Revenue Growth (3Y)(%) Range
Min: -47   Max: 65.8
Current: 6.7

-47
65.8
EBITDA Growth (3Y)(%) 10.30
BSTC's EBITDA Growth (3Y)(%) is ranked higher than
83% of the 856 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. BSTC: 10.30 )
BSTC' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 166.8
Current: 10.3

0
166.8
EPS Growth (3Y)(%) -11.40
BSTC's EPS Growth (3Y)(%) is ranked higher than
74% of the 824 Companies
in the Global Biotechnology industry.

( Industry Median: -4.80 vs. BSTC: -11.40 )
BSTC' s 10-Year EPS Growth (3Y)(%) Range
Min: -44.2   Max: 76.5
Current: -11.4

-44.2
76.5
» BSTC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

BSTC Guru Trades in Q2 2014

Jim Simons 67,009 sh (+349.72%)
Chuck Royce 100,000 sh (unchged)
» More
Q3 2014

BSTC Guru Trades in Q3 2014

Jim Simons 109,000 sh (+62.66%)
Chuck Royce 86,600 sh (-13.40%)
» More
Q4 2014

BSTC Guru Trades in Q4 2014

Jim Simons 145,101 sh (+33.12%)
Chuck Royce 48,600 sh (-43.88%)
» More
Q1 2015

BSTC Guru Trades in Q1 2015

Jim Simons 179,200 sh (+23.50%)
Chuck Royce 48,600 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with BSTC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 44.90
BSTC's P/E(ttm) is ranked higher than
92% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. BSTC: 44.90 )
BSTC' s 10-Year P/E(ttm) Range
Min: 14.34   Max: 109.97
Current: 44.9

14.34
109.97
Forward P/E 51.02
BSTC's Forward P/E is ranked higher than
88% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. BSTC: 51.02 )
N/A
PE(NRI) 44.70
BSTC's PE(NRI) is ranked higher than
93% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. BSTC: 44.70 )
BSTC' s 10-Year PE(NRI) Range
Min: 15.05   Max: 108.5
Current: 44.7

15.05
108.5
P/B 7.80
BSTC's P/B is ranked higher than
61% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 6.60 vs. BSTC: 7.80 )
BSTC' s 10-Year P/B Range
Min: 4.65   Max: 525
Current: 7.8

4.65
525
P/S 16.40
BSTC's P/S is ranked higher than
71% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 40.71 vs. BSTC: 16.40 )
BSTC' s 10-Year P/S Range
Min: 2.57   Max: 75
Current: 16.4

2.57
75
POCF 65.98
BSTC's POCF is ranked higher than
91% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. BSTC: 65.98 )
BSTC' s 10-Year POCF Range
Min: 1.05   Max: 3172
Current: 65.98

1.05
3172
EV-to-EBIT 25.30
BSTC's EV-to-EBIT is ranked higher than
95% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. BSTC: 25.30 )
BSTC' s 10-Year EV-to-EBIT Range
Min: -124.1   Max: 63.9
Current: 25.3

-124.1
63.9
Shiller P/E 85.60
BSTC's Shiller P/E is ranked higher than
94% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. BSTC: 85.60 )
BSTC' s 10-Year Shiller P/E Range
Min: 66.64   Max: 1000
Current: 85.6

66.64
1000
Current Ratio 31.82
BSTC's Current Ratio is ranked higher than
97% of the 1464 Companies
in the Global Biotechnology industry.

( Industry Median: 4.49 vs. BSTC: 31.82 )
BSTC' s 10-Year Current Ratio Range
Min: 0.43   Max: 37.48
Current: 31.82

0.43
37.48
Quick Ratio 31.82
BSTC's Quick Ratio is ranked higher than
98% of the 1464 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. BSTC: 31.82 )
BSTC' s 10-Year Quick Ratio Range
Min: 0.41   Max: 37.48
Current: 31.82

0.41
37.48
Days Sales Outstanding 78.88
BSTC's Days Sales Outstanding is ranked higher than
79% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 141.98 vs. BSTC: 78.88 )
BSTC' s 10-Year Days Sales Outstanding Range
Min: 5.36   Max: 299.91
Current: 78.88

5.36
299.91

Valuation & Return

vs
industry
vs
history
Price/Net Cash 11.55
BSTC's Price/Net Cash is ranked higher than
76% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 440.10 vs. BSTC: 11.55 )
BSTC' s 10-Year Price/Net Cash Range
Min: 2.84   Max: 65.22
Current: 11.55

2.84
65.22
Price/Net Current Asset Value 9.38
BSTC's Price/Net Current Asset Value is ranked higher than
77% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 48.94 vs. BSTC: 9.38 )
BSTC' s 10-Year Price/Net Current Asset Value Range
Min: 1.05   Max: 40.52
Current: 9.38

1.05
40.52
Price/Tangible Book 7.86
BSTC's Price/Tangible Book is ranked higher than
66% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 10.70 vs. BSTC: 7.86 )
BSTC' s 10-Year Price/Tangible Book Range
Min: 0.59   Max: 475
Current: 7.86

0.59
475
Price/DCF (Projected) 10.44
BSTC's Price/DCF (Projected) is ranked higher than
91% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. BSTC: 10.44 )
BSTC' s 10-Year Price/DCF (Projected) Range
Min: 0.66   Max: 188.89
Current: 10.44

0.66
188.89
Price/Median PS Value 1.13
BSTC's Price/Median PS Value is ranked higher than
83% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. BSTC: 1.13 )
BSTC' s 10-Year Price/Median PS Value Range
Min: 0.04   Max: 4.2
Current: 1.13

0.04
4.2
Price/Graham Number 3.84
BSTC's Price/Graham Number is ranked higher than
92% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. BSTC: 3.84 )
BSTC' s 10-Year Price/Graham Number Range
Min: 0.86   Max: 8.67
Current: 3.84

0.86
8.67
Earnings Yield (Greenblatt) 4.00
BSTC's Earnings Yield (Greenblatt) is ranked higher than
94% of the 1456 Companies
in the Global Biotechnology industry.

( Industry Median: -5.50 vs. BSTC: 4.00 )
BSTC' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.6   Max: 1259.6
Current: 4

1.6
1259.6

Business Description

Industry: Biotechnology » Biotechnology
Compare:NONOF, AMGN, GILD, BIIB, CELG » details
BioSpecifics Technologies Corp was incorporated in Delaware in 1990. It is a biopharmaceutical company engaged in the development of an injectable collagenase for multiple indications. The Company has a development and license agreement with Auxilium Pharmaceuticals, Inc. for injectable collagenase for indications in development. Auxilium is currently selling XIAFLEX in the U.S. for the treatment of Dupuytren's contracture and Peyronie's disease. In December 2013, FDA approved Auxilium's supplemental Biologics License Application ('sBLA') for XIAFLEX for the treatment of Peyronie's disease. The Company and its licensees face competition from larger pharmaceutical companies, specialty pharmaceutical companies and biotechnology firms, universities and other research institutions and government agencies that are developing and commercializing pharmaceutical products. As a biopharmaceutical company, the Company is subject to a large body of legal and regulatory requirements.
» More Articles for BSTC

Headlines

Articles On GuruFocus.com
BioSpecifics Technologies Corp. Reports Operating Results (10-Q) Aug 09 2010 
BioSpecifics Technologies Corp. Reports Operating Results (10-Q) Aug 13 2009 
BioSpecifics Technologies Corp. Reports Operating Results for Fiscal Quarter Ended on 2008-03-31 Jan 13 2009 
BioSpecifics Technologies Corp. Reports Operating Results for Fiscal Quarter Ended on 2008-06-30 Jan 13 2009 
BioSpecifics Technologies Corp. Reports Operating Results for Fiscal Quarter Ended on 2008-09-30 Jan 13 2009 
BioSpecifics Technologies Corp. Announces Listing on NASDAQ Global Market Jan 06 2009 

More From Other Websites
BIOSPECIFICS TECHNOLOGIES CORP Financials May 20 2015
BIOSPECIFICS TECHNOLOGIES CORP Files SEC form 8-K, Results of Operations and Financial Condition,... May 20 2015
BioSpecifics Reports Presentation of First Ever Treatment Guidelines for Peyronie's Disease and... May 19 2015
BioSpecifics Reports Presentation of First Ever Treatment Guidelines for Peyronie's Disease and... May 19 2015
BIOSPECIFICS TECHNOLOGIES CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements... May 18 2015
BioSpecifics posts 1Q profit May 11 2015
BioSpecifics posts 1Q profit May 11 2015
BIOSPECIFICS TECHNOLOGIES CORP Files SEC form 8-K, Results of Operations and Financial Condition,... May 11 2015
BioSpecifics Technologies Corp. Reports First Quarter 2015 Financial Results May 11 2015
BioSpecifics Technologies Corp. Reports First Quarter 2015 Financial Results May 11 2015
BioSpecifics Technologies Corp. to Present at the 2015 UBS Global Healthcare Conference May 11 2015
BioSpecifics Technologies Corp. to Present at the 2015 UBS Global Healthcare Conference May 11 2015
Q1 2015 Biospecifics Technologies Corp Earnings Release - After Market Close May 11 2015
BIOSPECIFICS TECHNOLOGIES CORP Files SEC form 10-Q, Quarterly Report May 11 2015
BioSpecifics Technologies Corp. to Report First Quarter 2015 Financial Results on Monday, May 11,... May 04 2015
BioSpecifics Technologies Corp. to Report First Quarter 2015 Financial Results on Monday, May 11,... May 04 2015
BioSpecifics Announces Appointment of Jennifer Chao and Jyrki Mattila, M.D., Ph.D. to Board of... Apr 22 2015
BIOSPECIFICS TECHNOLOGIES CORP Files SEC form 8-K, Change in Directors or Principal Officers,... Apr 22 2015
BioSpecifics Announces Appointment of Jennifer Chao and Jyrki Mattila, M.D., Ph.D. to Board of... Apr 22 2015
BIOSPECIFICS TECHNOLOGIES CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements... Apr 13 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK